Patent · US Active

Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods

US8404267B2 · kind B2 · utility

2Cited by

135References

3Claims

0Family size

Assignee

Allergan, Inc. · US

Inventors

Patrick M. Hughes · Aliso Viejo, US
Thomas C. Malone · Irvine, US
Gerald W. De Vries · Laguna Hills, US
Jeffery L. Edelman · Irvine, US
Joan-En Chang-Lin · Tustin, US
Jane-Guo Shiah · Irvine, US
Thierry Nivaggioli · San Francisco, US

Key dates

Filing date	Feb 11, 2008
Grant date	Mar 26, 2013
Priority date	—
Expiry date	Feb 22, 2031

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY10T428/2985
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.